Abstract

The ability to make treatment recommendations for patients with gastrointestinal lymphoma is hampered by a lack of prospective trials and by a lack of uniformity in classification and staging. Patients with gastric diffuse large B-cell lymphoma have traditionally been treated with surgery and many physicians continue to recommend this approach. However, recent data suggest that these patients can be treated with combination chemotherapy regimens in the same manner as patients with nodal presentations of diffuse large B-cell lymphoma. There is evidence to suggest that adjuvant radiotherapy may improve the outcome for these patients. The recognition that extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue is a distinct clinicopathologic entity and the elucidation of the pathogenic role of Helicobacter pylori has revolutionized the treatment of these gastric lymphomas. Patients with localized disease should be managed with antibiotic therapy initially. Radiation therapy is extremely effective for these patients, but it should probably be reserved for patients who fail anti-H. pylori treatment.

Original languageEnglish (US)
Pages (from-to)421-430
Number of pages10
JournalCurrent treatment options in oncology
Volume4
Issue number5
DOIs
StatePublished - Jan 1 2003

Fingerprint

Lymphoma
Marginal Zone B-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Helicobacter pylori
Adjuvant Radiotherapy
Therapeutics
Combination Drug Therapy
Stomach
Radiotherapy
Anti-Bacterial Agents
Physicians

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Gastrointestinal lymphoma. / Bierman, Philip Jay.

In: Current treatment options in oncology, Vol. 4, No. 5, 01.01.2003, p. 421-430.

Research output: Contribution to journalReview article

@article{42cd1cb80f7142388a24fd9d68050587,
title = "Gastrointestinal lymphoma.",
abstract = "The ability to make treatment recommendations for patients with gastrointestinal lymphoma is hampered by a lack of prospective trials and by a lack of uniformity in classification and staging. Patients with gastric diffuse large B-cell lymphoma have traditionally been treated with surgery and many physicians continue to recommend this approach. However, recent data suggest that these patients can be treated with combination chemotherapy regimens in the same manner as patients with nodal presentations of diffuse large B-cell lymphoma. There is evidence to suggest that adjuvant radiotherapy may improve the outcome for these patients. The recognition that extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue is a distinct clinicopathologic entity and the elucidation of the pathogenic role of Helicobacter pylori has revolutionized the treatment of these gastric lymphomas. Patients with localized disease should be managed with antibiotic therapy initially. Radiation therapy is extremely effective for these patients, but it should probably be reserved for patients who fail anti-H. pylori treatment.",
author = "Bierman, {Philip Jay}",
year = "2003",
month = "1",
day = "1",
doi = "10.1007/s11864-003-0043-6",
language = "English (US)",
volume = "4",
pages = "421--430",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Gastrointestinal lymphoma.

AU - Bierman, Philip Jay

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The ability to make treatment recommendations for patients with gastrointestinal lymphoma is hampered by a lack of prospective trials and by a lack of uniformity in classification and staging. Patients with gastric diffuse large B-cell lymphoma have traditionally been treated with surgery and many physicians continue to recommend this approach. However, recent data suggest that these patients can be treated with combination chemotherapy regimens in the same manner as patients with nodal presentations of diffuse large B-cell lymphoma. There is evidence to suggest that adjuvant radiotherapy may improve the outcome for these patients. The recognition that extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue is a distinct clinicopathologic entity and the elucidation of the pathogenic role of Helicobacter pylori has revolutionized the treatment of these gastric lymphomas. Patients with localized disease should be managed with antibiotic therapy initially. Radiation therapy is extremely effective for these patients, but it should probably be reserved for patients who fail anti-H. pylori treatment.

AB - The ability to make treatment recommendations for patients with gastrointestinal lymphoma is hampered by a lack of prospective trials and by a lack of uniformity in classification and staging. Patients with gastric diffuse large B-cell lymphoma have traditionally been treated with surgery and many physicians continue to recommend this approach. However, recent data suggest that these patients can be treated with combination chemotherapy regimens in the same manner as patients with nodal presentations of diffuse large B-cell lymphoma. There is evidence to suggest that adjuvant radiotherapy may improve the outcome for these patients. The recognition that extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue is a distinct clinicopathologic entity and the elucidation of the pathogenic role of Helicobacter pylori has revolutionized the treatment of these gastric lymphomas. Patients with localized disease should be managed with antibiotic therapy initially. Radiation therapy is extremely effective for these patients, but it should probably be reserved for patients who fail anti-H. pylori treatment.

UR - http://www.scopus.com/inward/record.url?scp=0142244512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142244512&partnerID=8YFLogxK

U2 - 10.1007/s11864-003-0043-6

DO - 10.1007/s11864-003-0043-6

M3 - Review article

VL - 4

SP - 421

EP - 430

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 5

ER -